Allakos LLC, formerly known as Allakos Inc. is a biotechnology company. The Company is developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 21:00:00 14/05/2025 BST			5-day change	1st Jan Change
0.3291 ^USD	-0.06%		-.--%	-

15/05/25	Allakos Inc. Announces Resignation of Dr. Robert Alexander as CEO	CI
15/05/25	Allakos Inc. Announces Resignation of Baird Radford as CFO	CI

Market Cap	29.74M 25.73M 24.03M 22.04M 41.45M 2.83B 42.11M 282M 111M 1.42B 112M 109M 4.69B	P/E 2023	-1.28x	P/E 2024	-0.93x
Enterprise Value	-46.92M -40.58M -37.9M -34.77M -65.39M -4.47B -66.43M -445M -175M -2.24B -176M -172M -7.4B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	96.57%	Yield 2023 *	-	Yield 2024	-

15/05/25	Allakos Inc. Announces Resignation of Dr. Robert Alexander as CEO	CI
15/05/25	Allakos Inc. Announces Resignation of Baird Radford as CFO	CI
15/05/25	Allakos Inc. Announces Executive Changes	CI
14/05/25	Allakos Inc.(NasdaqGS:ALLK) dropped from NASDAQ Composite Index	CI
14/05/25	Concentra Biosciences, LLC completed the acquisition of Allakos Inc..	CI
08/05/25	Allakos Inc.(NasdaqGS:ALLK) dropped from S&P TMI Index	CI
07/05/25	Allakos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
02/04/25	Allakos to Be Acquired by Concentra Biosciences for $0.33 per Share	MT
02/04/25	Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences	RE
01/04/25	Concentra Biosciences, LLC entered into an agreement to acquire Allakos Inc. for $31 million.	CI
12/03/25	Allakos Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
12/03/25	Allakos Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	CI
27/01/25	Top Midday Decliners	MT

17/01/24	Barclays Trims Allakos' Price Target to $1 From $1.50, Maintains Underweight Rating	MT
17/01/24	JMP Securities Adjusts Allakos' Price Target to $3 From $10, Maintains Market Outperform Rating	MT
17/01/24	Jefferies Downgrades Allakos to Hold From Buy, Adjusts Price Target to $1.50 From $6	MT
16/01/24	Cantor Fitzgerald Downgrades Allakos to Neutral From Overweight	MT
16/01/24	Lifesci Capital Downgrades Allakos to Market Perform From Outperform	MT

Allakos Inc. Share Price

Stocks

ALLK

US01671P1003

Biotechnology & Medical Research

Valuation: Allakos Inc.

Latest news : Allakos Inc.

Analysts' recommendations: Allakos Inc.

Press Releases: Allakos Inc.

News in other languages: Allakos Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Allakos Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

22/07/22	Lonza-Aktien sinken nach Halbjahreszahlen
05/12/19	EN DIRECT DES MARCHES : Kering / Moncler, FDJ, Engie, Capgemini, Cybergun, Amazon, Fiat Chrysler...
05/12/19	Des marchés moins cyclothymiques pour finir la semaine ?

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/05/25	Steven James	Issuer sale	Director	332,932	0.3726%
15/05/25	Neil Graham	Issuer sale	Director	195,786	0.2191%
15/05/25	BVF Partners LP	Issuer sale	Company	16,312,872	18.2586%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALLAKOS INC.	-0.06%	-.--%	-.--%	-93.89%	29.74M
LONZA GROUP AG	+0.99%	+1.78%	+5.07%	+16.49%	49.47B
REVOLUTION MEDICINES, INC.	+3.71%	+9.40%	+486.14%	+579.98%	43.61B
BEONE MEDICINES AG	+5.60%	+10.21%	+20.85%	+81.78%	39.6B
IQVIA HOLDINGS INC.	+2.70%	+1.57%	+32.71%	+9.07%	39.29B
CELLTRION, INC.	+2.21%	+6.75%	+20.20%	+54.40%	32.43B
ASCENDIS PHARMA A/S	+2.23%	+4.71%	-	-	16.84B
MEDPACE HOLDINGS, INC.	+0.97%	+2.35%	+35.99%	+124.45%	16.49B
EUROFINS SCIENTIFIC SE	-0.11%	+2.41%	+5.03%	+20.47%	14.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.75%	+15.04%	+79.84%	+29.70%	12.77B
Average	+1.90%	+5.69%	+76.20%	+91.38%	26.45B
Weighted average by Cap.	+2.54%	+6.10%	+104.57%	+138.01%

	2023	2024
Net sales	-	-
Net income	-186M -161M -150M -138M -259M -17.67B -263M -1.76B -691M -8.86B -697M -682M -29.29B	-116M -100M -93.56M -85.82M -161M -11.02B -164M -1.1B -431M -5.52B -435M -425M -18.26B
Net Debt	-129M -112M -104M -95.84M -180M -12.31B -183M -1.23B -481M -6.17B -486M -475M -20.4B	-76.66M -66.31M -61.93M -56.81M -107M -7.3B -109M -727M -285M -3.66B -288M -282M -12.09B

3 years	0.22	4.96
5 years	0.22	112.87
10 years	0.22	157.98